Last reviewed · How we verify
tenofovir + abacavir + efavirenz
tenofovir + abacavir + efavirenz is a Antiretroviral combination therapy (NRTI + NNRTI) Small molecule drug developed by Hospital Clinic of Barcelona. It is currently FDA-approved for HIV-1 infection in treatment-naïve and treatment-experienced patients.
This combination of three antiretroviral drugs inhibits HIV replication by blocking reverse transcriptase and integrase enzymes, preventing the virus from copying its genetic material and integrating into host cells.
This combination of three antiretroviral drugs inhibits HIV replication by blocking reverse transcriptase and integrase enzymes, preventing the virus from copying its genetic material and integrating into host cells. Used for HIV-1 infection in treatment-naïve and treatment-experienced patients.
At a glance
| Generic name | tenofovir + abacavir + efavirenz |
|---|---|
| Sponsor | Hospital Clinic of Barcelona |
| Drug class | Antiretroviral combination therapy (NRTI + NNRTI) |
| Target | HIV reverse transcriptase |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease / Virology |
| Phase | FDA-approved |
Mechanism of action
Tenofovir and abacavir are nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) that compete with natural substrates to block reverse transcriptase activity. Efavirenz is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that binds directly to reverse transcriptase and inhibits its function. Together, these three agents provide complementary inhibition of HIV replication through multiple mechanisms targeting the same enzyme complex.
Approved indications
- HIV-1 infection in treatment-naïve and treatment-experienced patients
Common side effects
- Dizziness and CNS effects
- Nausea
- Rash
- Headache
- Fatigue
- Elevated liver enzymes
- Lipodystrophy
- Lactic acidosis
Key clinical trials
- Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV (PHASE2, PHASE3)
- A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments (PHASE4)
- Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy
- Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen (PHASE2, PHASE3)
- Research on the Psychological Status of Patients With HIV-1 Infection
- The Effect of Aspirin on HIV Disease Progression Among HIV- Infected Individuals Initiating Anti- Retroviral Therapy (PHASE2)
- Anti-HIV Drug Regimens and Treatment-Switching Guidelines in HIV Infected Children (PHASE2, PHASE3)
- Study to Evaluate Switching From a Regimen of Two Nucleos(t)Ide Reverse Transcriptase Inhibitors (NRTI) Plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Participants (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- tenofovir + abacavir + efavirenz CI brief — competitive landscape report
- tenofovir + abacavir + efavirenz updates RSS · CI watch RSS
- Hospital Clinic of Barcelona portfolio CI
Frequently asked questions about tenofovir + abacavir + efavirenz
What is tenofovir + abacavir + efavirenz?
How does tenofovir + abacavir + efavirenz work?
What is tenofovir + abacavir + efavirenz used for?
Who makes tenofovir + abacavir + efavirenz?
What drug class is tenofovir + abacavir + efavirenz in?
What development phase is tenofovir + abacavir + efavirenz in?
What are the side effects of tenofovir + abacavir + efavirenz?
What does tenofovir + abacavir + efavirenz target?
Related
- Drug class: All Antiretroviral combination therapy (NRTI + NNRTI) drugs
- Target: All drugs targeting HIV reverse transcriptase
- Manufacturer: Hospital Clinic of Barcelona — full pipeline
- Therapeutic area: All drugs in Infectious Disease / Virology
- Indication: Drugs for HIV-1 infection in treatment-naïve and treatment-experienced patients
- Compare: tenofovir + abacavir + efavirenz vs similar drugs
- Pricing: tenofovir + abacavir + efavirenz cost, discount & access